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ABSTRACT 
Serum antioxidants may afford neuroprotection against Alzheimer’s disease (AD) via correction 
of the pro-oxidative imbalance but findings reported have been inconsistent.  We compared the 
2 
 
pooled mean difference in serum levels of ten dietary antioxidants between patients with AD and 
cognitively intact controls from 52 studies in meta-analyses using random-effects models. Patients 
with AD had significantly lower plasma levels of α-carotene, β -carotene, lycopene, lutein, vitamin 
A, C and E, and uric acid. No significant difference was observed for plasma levels of β –
cryptoxanthin and zeaxanthin. Considerable heterogeneity was detected across studies. The lower 
serum levels of dietary antioxidants from the carotene and vitamin subclasses observed in 
individuals with AD suggest reduced systemic availability of these subclasses in this prevalent 
form of dementia. To our knowledge, these are the first meta-analyses to demonstrate lower serum 
lycopene and to evaluate β-cryptoxanthin, lutein and zeaxanthin levels in AD. In light of the 
significant heterogeneity detected across studies, caution should be exercised in the interpretation 
of the data and therapeutic intervention approaches considered through supplementation measures. 
Our data may better inform interventions to improve antioxidant status in a condition of major 
public health importance. 
Keywords: Alpha-carotene; Beta-carotene; Beta-cryptoxanthin; Lutein; Lycopene; Uric Acid; 
Vitamin A; Vitamin C; Vitamin E; Zeaxanthin  
Abbreviations: AD, Alzheimer’s disease; UA, uric acid; OS, oxidative stress; ROS, reactive 
oxygen species; FVs, fruit and vegetables; MCI, mild cognitive impairment; 
PMD, pooled mean difference; CI, confidence interval; TAC, total antioxidant 
capacity.  
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INTRODUCTION 
An estimated 46 million people are affected worldwide by dementia, with 7.7 million new cases 
reported each year and numbers predicted to increase significantly through ageing populations [1]. 
Alzheimer's disease (AD) is the most common dementia subtype characterized by brain atrophy 
and accumulation of amyloid-plaques and neurofibrillary tangles throughout the cortex [2]. 
Multiple neuropathologic processes have been implicated in the onset of cognitive decline leading 
to this devastating disease, a process influenced by multiple modifiable and non-modifiable risk 
factors [1, 3].   
Oxidative stress (OS) is a pathophysiological imbalance in the production of reactive oxygen 
species (ROS) and antioxidants, in favor of the former which has been implicated early in the 
dementia disease etiology [4].  Cerebral tissue is especially vulnerable to ROS due to its high 
content of polyunsaturated fatty acids and relatively low levels of antioxidants to cope with its 
high metabolic activity. Oxidative damage results from this antioxidant deficit leading to neuronal 
cell death and subsequent depletion in antioxidant defenses in the brain and circulation of patients 
with AD [4-5]. The body produces some endogenous antioxidants, however less potent dietary 
antioxidants are required for additional protective support to scavenge active radicals [6]. 
The main classes of exogenous antioxidants include polyphenols, vitamins and carotenoids. Major 
sources of polyphenols, or more specifically flavonoids, include chocolate, wine and green tea. 
Vitamin E,  one of the most promising vitamins in AD research can be found in whole grains such 
as cereals and high quality vegetable oils. Fruit and vegetables (FVs) are major dietary sources of 
carotenoids, comprising of two subclasses, namely xanthophylls and carotenes. Furthermore, 
adequate consumption of FVs as well as nutritional supplementation has shown to be effective in 
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potentiating plasma antioxidant levels [7].  Individuals with AD have been identified as a high-
risk group for having poor diets lacking in FVs with FV intake previously reported to be associated 
with cognitive function [8]. Nutritional influences in AD have the potential to bear major public 
health significance therefore we have focused on consequential serum antioxidant status rather 
than dietary intake as a more objective measure.  
There has been significant interest in observational studies assessing the association between 
serum levels of antioxidants and AD given their potential neuroprotective effect. Despite numerous 
epidemiological studies over the past three decades, no definitive evidence is available. This may 
be partly due to the major limitation of retrospective case control studies whereby the degree of 
oxidative damage and subsequent cognitive impairment is often not assessed until the point of AD 
diagnosis in the cases which is believed to predate many of the clinical signs associated with the 
disease. This will not manifest to the same extent in controls and, in the presence of such 
deferential misclassification, estimates of the association between serum antioxidant status and 
AD will be biased upwards making the results of retrospective studies difficult to interpret. This 
problem has been overcome by the addition of more recent case control studies nested within 
prospective cohorts where blood samples are collected closer to the time of onset of cognitive 
decline. 
Two previous meta-analyses, the former including 80 studies published up to March 2012 and a 
more recent publication including 65 studies published up to August 2012, both reported negative 
associations between serum levels of antioxidants and AD although deemed the quality of evidence 
to be low [9, 10].  Furthermore, randomized controlled trials (RCTs) evaluating antioxidant 
supplementation have failed to substantiate the findings from observational studies through 
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improved cognitive function measures [11, 12]. Further investigation of the epidemiological data 
available is necessary to improve our understanding of the complexity of these associations, given 
the contrast in previous findings.  
Both publications combined largely retrospective studies on several dietary antioxidants within the 
various subclasses. Since then, at least 8 new case-control studies have confirmed or refuted an 
association between serum antioxidant status and AD. We therefore conducted a large-scale 
analysis using data obtained from prospective and retrospective studies from 1991 to 2016 to 
evaluate the magnitude of this relationship more precisely and assess the grouped mean difference 
in relevant subgroups, where applicable.  
As such, we have compared the plasma antioxidant status of individuals with AD and cognitively 
intact controls from 52 published studies using random effects meta-analysis of ten antioxidants. 
We report on antioxidant vitamins (serum vitamins A, C and E) and the serum carotenoids (lutein, 
zeaxanthin, b–cryptoxanthin of the xanthophyll subclass and α-carotene, β-carotene and lycopene 
of the carotene subclass, along with uric acid). 
 
MATERIAL AND METHODS 
We undertook a systematic review and meta-analysis according to the guidelines of the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [13]. 
Literature search strategy and selection criteria  
Literature published in English from 1970 to September 30th 2016, was systematically screened 
by two reviewers (KM and GMK) in PubMed, Embase, SCOPUS and ISI Web of Science 
electronic databases using the following search terms in the title, abstract or descriptors:  
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[(Alzheimer OR dementia) AND (serum OR plasma OR blood) AND (carotene OR carotenoids 
OR cryptoxanthin OR lutein OR xanthophyll OR lycopene OR uric acid OR urate OR retinol OR 
retinoic OR vitamin A OR ascorbate OR ascorbic acid OR vitamin C OR tocopherol OR vitamin 
E OR zeaxanthin)].The following inclusion criteria were used: (1) contained an AD population 
defined using a clearly stated AD diagnostic criteria; (2) mentioned the use of a cognitively intact 
elderly control group; (3) reported summary statistic values of plasma antioxidant levels for AD 
cases and controls; (4) estimated plasma antioxidants levels using established analysis methods, 
(5) stated the number of AD cases and controls, and (6) stated the mean age or age range of case 
and control groups. The diagnosis of AD was not limited to any specific diagnostic criteria or 
method of plasma/serum antioxidant measurement. The following publications were excluded: 
those concerning other cognitive disorders (e.g. mild cognitive impairment [MCI], frontotemporal 
dementia, vascular dementia, or combination of AD and dementia subtypes), those where the 
control group was not cognitively intact and those that included subjects using vitamin 
supplements as an adjuvant treatment to slow AD progression. 
Data extraction 
Two reviewers (KM and GMK) evaluated the eligibility of potentially relevant documents 
independently, and any discrepancies were discussed with a third reviewer (CC) until a clear 
consensus was reached. On closer analysis of the retrieved studies, it became apparent that some 
publications contained data derived from the same study population. Only the study with the most 
complete set of data was included. Furthermore, it was also observed that some of the studies had 
incomplete data fields and, where direct correspondence with the authors for additional data was 
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unsuccessful, these studies were excluded. The aforementioned limitations excluded a further nine 
studies.  
For each antioxidant, the following study characteristics were extracted from publications using a 
predesigned form (see supplementary material): (1) name of first author, (2) publication year, (3) 
matching factors, (4) mean age or age range of cases and controls, (5) method of plasma 
antioxidant level measurement, (6) number of AD cases and cognitively intact controls, and (7) 
plasma antioxidant values.  
The plasma antioxidant data was compiled and presented as summary statistics (N, mean and 
standard deviation [SD]). For studies reporting non-parametric summary data, normal distribution 
was assumed to allow conversion to parametric summary statistics using established methods. 
Several studies reported on multiple groups of AD patients subdivided by disease severity, stage 
or APOE genotype; in these circumstances, the mean of all subgroup summary data was calculated 
to obtain an average summary statistic for cases in the study. Further methodological details 
regarding data extraction and manipulation are provided in the supplemental material.  
Data synthesis and meta-analysis 
Meta-analysis was performed when four or more publications were retrieved for a specific 
antioxidant. Identical measurement units were required to analyse results by pooled mean 
difference (PMD) for each study. To enable cross study comparison, plasma antioxidant values 
were expressed in Standard International System of Units of micromoles per liter (moles/liter). 
Accordingly, a conversion was performed for those studies reporting data in the conventional units 
using a value specific to the antioxidant under investigation (see supplementary data). To compare 
the plasma/serum levels of individuals with AD with cognitively normal controls, all reported 
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antioxidant values were integrated and summarized for the pooled population expressed as PMD 
with 95% confidence intervals (95% CI) using meta-analysis (regression) methods, according to 
the PRISMA statement [13]. These estimates were combined using random-effects meta-analysis 
models implemented by Review Manager (RevMan) [Computer program], Version 5.3 [14]. 
Publication bias was analyzed for each outcome through visual analysis of funnel plots and the I2 
statistic to detect the presence of heterogeneity across included studies and quantify the percentage 
of variability attributed to between-study differences. Heterogeneity among studies was also 
evaluated using the Chi-square test based on Cochran’s Q statistic. In addition, sensitivity analyses 
were conducted by omitting one study per iteration and recalculating to determine if an individual 
study significantly affected the pooled estimate. Further details on the search strategy, data 
extraction, analysis techniques, tests of heterogeneity and lists of excluded publications is provided 
(supplementary material).  
 
RESULTS 
A total of 2,508 articles were identified, 2,489 by initial keyword search and an additional 20 from 
published reference lists. Duplicate articles (1,754) were removed and the title and abstract of the 
remaining 755 publications were screened and evaluated according to predefined inclusion and 
exclusion criteria with no restriction based on year (Figure 1). Included were case-control studies 
with human subjects that may have contained plasma antioxidant measurements of individuals 
with AD and cognitively normal controls, even if not explicit in the abstract. Excluded were 
conference papers, reviews, abstracts, and those not written in English (n=653). Studies with non-
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human subjects were also excluded. This left 102 full text articles for consideration with 52 
retained for inclusion within the systematic review. 
Included publications reported at least one plasma antioxidant level providing information on the 
following antioxidants; α-carotene (8 studies) [15-22], β-carotene (13 studies) [15-22, 24-28], 
lycopene (7 studies) [15, 18-20, 22, 27, 28], β-cryptoxanthin (4 studies) [18-20, 22], lutein (5 
studies) [18-20, 22-23], zeaxanthin (5 studies) [18-20, 22-23], vitamin A (15 studies) [15, 16, 18-
21, 24, 26, 29-35], vitamin C (16 studies) [15, 17-21, 25, 27-29, 31, 35-39] vitamin E (31 studies) 
[15, 17-20, 24-35, 38-51] and uric acid (21 studies) [15, 18-20, 33, 42-43, 49, 52-63]. The summary 
results for each antioxidant are provided in Table 1.  
Antioxidants were considered within their dietary classes, namely carotenoids and vitamins. The 
carotenoid class can be further divided into two subclasses based on polarity: carotenes and their 
oxygenated derivatives, xanthophylls. The carotene subclass consists of α-carotene, β-carotene and 
lycopene; xanthophylls include β-cryptoxanthin, lutein and zeaxanthin and vitamins encompass 
vitamin A, vitamin C and vitamin E. Although regarded as an endogenous antioxidant, uric acid 
(UA) was also included in the meta-analysis as a proxy for total antioxidant capacity (TAC) given 
its significant role in free radical scavenging and providing 60–80% of TAC in plasma [64]. 
Results identified significantly lower plasma α-carotene, β-carotene, lycopene, uric acid, vitamins 
A, C and E in individuals with AD compared to cognitively intact controls.  
Carotenes 
Significantly lower plasma levels were observed between AD cases and cognitively intact controls 
for all three members of this subclass on pooled analysis of each antioxidant. 
Alpha-carotene 
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There was variation in the reported associations observed across all eight studies containing 327 
AD patients and 267 cognitively intact controls with four describing lower plasma α-carotene 
levels in AD patients compared to non-demented controls [17-20]. No significant difference was 
reported across four additional studies [15, 16, 21-22]. On pooled analysis, plasma α-carotene 
levels were 0.03 moles/l lower in cases versus controls (95% CI: -0.05, -0.01; P = 0.002; Table 
1, Figure 2a). Significant heterogeneity was observed between studies (I2= 79%, P < 0.00001), 
although sensitivity analysis through the omission of one study per iteration, showed no significant 
change in the PMD.  
Beta-carotene 
Five studies reported lower plasma β-carotene levels in AD patients [16, 18, 24, 26-27] whereas 
eight found no significant difference between cases and controls [15, 17, 19-22, 25, 28]. The PMD 
for the thirteen studies with 701 AD patients and 633 cognitively intact controls using a random-
effects model showed beta-carotene levels were 0.11 moles/l lower in cases versus controls (95% 
CI: -0.17, -0.04; P = 0.0008; Table 1, Figure 2b). Significant heterogeneity was observed (I2= 86%, 
P < 0.00001), although in a sensitivity analysis, no single study was found responsible.  
Lycopene 
Pooled meta-analysis of seven studies with 424 AD patients and 319 cognitively intact controls 
showed that individuals with AD had 0.15 moles/l lower levels of lycopene (95% CI: -0.27, -
0.02; P = 0.02; Table 1, Figure 2c) than cognitively intact controls. Individually, two studies 
reported lower plasma lycopene levels in AD cases [18-19] and five reported no difference [15, 
20, 22, 27, 28]. Significant heterogeneity was observed among studies (I2= 95%, P < 0.00001). In 
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a sensitivity analysis, the PMD was no longer significant following omission of studies by Mecocci 
et al [18] and Polidori et al. [19]. 
Xanthophylls  
Significantly lower lutein plasma levels were observed between AD cases and cognitively intact 
controls on pooled analysis The differences observed in the plasma levels of beta-cryptoxanthin 
and zeaxanthin did not reach significance on pooled analysis of each antioxidant.  
Beta-cryptoxanthin 
The levels of β-cryptoxanthin in AD subjects was analysed in four studies with two reporting a 
significant reduction in those with AD [18, 20] and two showing no significant difference [19, 22]. 
Cumulatively with 174 individuals with AD and 145 cognitively intact controls, there was no 
significant difference in beta-cryptoxanthin (PMD: -0.13 moles/l, 95% CI: -0.28, 0.01; P = 0.08; 
Table 1, Figure 3a). Significant heterogeneity was observed across studies (I2= 93%, P < 0.00001). 
In a sensitivity analysis, a significant difference was detected following omission of the study by 
Wang et al (PMD: -0.19 moles/l; (95% CI: -0.35, -0.03; P = 0.02) [22].  
Lutein  
Plasma lutein from AD subjects was evaluated in five studies with 210 AD patients and 178 
cognitively intact controls, three reported a significant reduction in AD patients [19-20, 23] while 
two showed no significant difference [18, 22]. Collectively, a significant difference in plasma 
lutein levels in AD was found. (PMD -0.13, 95% CI: -0.23, -0.03, P = 0.01; Table 1, Figure 3b). 
Heterogeneity within the five studies was high, (I2= 88%, P < 0.0001). Again, omission of the 
study by Wang et al. in the sensitivity analysis highlighted a significant lower level of plasma 
lutein in AD patients [22].  
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Zeaxanthin 
Of the five studies evaluating plasma zeaxanthin levels in AD with 210 AD patients and 178 
cognitively intact controls,; three reported significantly lower levels amongst AD subjects 
compared with controls [18, 20, 23]. In the other two studies [19, 22], no significant difference 
was found in plasma zeaxanthin levels between the two groups. Collectively there was no 
significant difference in plasma zeaxanthin levels (PMD -0.03 moles/l, 95% CI: -0.07, 0.00, P = 
0.06; Table 1, Figure 3c). Significant heterogeneity was detected, (I2= 94%, P < 0.0001) and again 
omission of the study by Wang et al. identified a significantly lower level of serum zeaxanthin in 
those with AD [22].  
Vitamins  
AD patients showed significantly lower levels of all members of this subclass when compared 
with controls (P < 0.00001).   
Vitamin A 
Fifteen studies were identified that measured plasma vitamin A levels in AD with 752 AD patients 
and 1,104 cognitively intact controls; nine reporting significantly lower levels in AD [15-16, 18, 
20, 24-25, 29-30, 35] and six reporting no significant difference between AD patients and 
cognitively intact controls [19, 21, 31-34]. Pooled analysis suggested lower vitamin A levels in 
AD with PMD -0.26 moles/l (95% CI: -0.33, -0.18, P < 0.00001; Table 1, Figure 4a). Sensitivity 
analysis failed to identify a specific publication to account for the considerable heterogeneity 
detected. (I2= 88%, p<0.0001). 
Vitamin C 
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Pooled analysis of the sixteen studies with 623 AD patients and 491 cognitively intact controls 
revealed lower plasma levels of Vitamin C in those with AD compared to non-demented controls 
(PMD -12.58 moles/l, 95% Cl -17.73, -7.43, P < 0.00001; Table 1, Figure 4b). Individually, nine 
studies reported significantly lower levels in patients with AD [15, 18-20, 27, 29, 31, 35, 38] while 
the remaining seven studies found no significant difference between groups [17, 21, 25, 28, 36-37, 
39]. Significant heterogeneity was observed across studies (I2=95%, P < 0.00001) but sensitivity 
analysis failed to attribute this to a single study.  
Vitamin E 
Vitamin E was the most frequently investigated dietary antioxidant with 31 studies included with 
1,554 AD patients and 1,872 cognitively intact controls. Fifteen studies reported no significant 
difference between groups [17, 27, 29, 32, 34, 39-46, 48, 49], while sixteen studies found vitamin 
E to be lower in the plasma of AD patients than cognitively intact controls [15, 18-20, 24-26, 28, 
30-31, 33, 35, 38, 47, 50-51]. Pooled meta-analysis showed lower plasma vitamin E levels (5.26 
moles/l) in AD patients compared to cognitively intact controls (95% Cl -6.64, -3.89, P < 
0.00001; Table 1, Figure 4c). Significant heterogeneity was observed between studies with 
sensitivity analysis unable to attribute this to any specific publication.  
Uric Acid  
Twenty-one studies included uric acid measurements, with 1,110 AD patients and 2,384 
cognitively intact controls. Results were conflicting; twelve studies described lower plasma uric 
acid levels in AD [20, 35, 38, 43, 52, 54-55, 57-58, 60, 62-63], one study reported the opposite 
[15] and eight described no significant difference [19, 33, 42, 49, 53, 56, 59, 61]. In aggregation, 
this data suggested plasma uric acid was significantly lower in AD compared to controls with a 
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PMD -27.37 moles/l (95% CI: -49.75, -5.00, P = 0.02; Table 1, Figure 5). Significant 
heterogeneity was detected (I2= 98%, P < 0.0001) but no single study was identified as the main 
contributor to the heterogeneity observed.   
Publication bias 
Assessment of publication bias through visual analysis of funnel plots showed no evidence of 
asymmetrical distribution for the ten antioxidants considered (Supplemental Figures 2.2.1-10).   
 
DISCUSSION 
These meta-analyses considered 52 studies to compare the levels of ten plasma antioxidants in 
individuals with AD to those of cognitively intact controls. Our findings are consistent with 
previous meta-analyses, which pooled data on five of the nine exogenous antioxidants included in 
our study [9, 10]. We found significantly lower plasma levels of α-carotene, β-carotene,lycopene, 
lutein, vitamins A, C and E and uric acid among individuals with AD. To our knowledge, we 
present the first meta-analysis to combine evidence comparing plasma levels of four less well-
known carotenoids to include lycopene, a member of the carotene subclass which we found to be 
significantly reduced in the plasma of individuals with AD compared with cognitively intact 
controls.  Secondly, we present pooled data on three xanthophylls, a subclass which was not 
included in previous meta-analyses in this area of research.  Our pooled analysis found lutein to 
be significantly reduced in AD while zeaxanthin and β-cryptoxanthin, despite showing decreased 
levels in AD versus controls, failed to reach the established significance threshold. 
The importance of antioxidative vitamins in AD is predominantly due to their biological roles in 
maintaining neuronal integrity and preventing cell loss, nevertheless the findings previously 
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reported have not always been consistent [9, 10]. When meta-analyzed, concentrations of each 
vitamin were significantly lower in AD, with vitamin E levels particularly important, given its 
contribution to total antioxidant defenses as the most potent radical-scavenging lipophilic 
antioxidant.  
Uric acid, an endogenous antioxidant and the main end product of purine metabolism, was chosen 
as a proxy measure given its strong correlation with TAC [64]. Uric acid combats oxidative stress 
through multiple mechanisms including elimination of reactive oxygen and nitrogen species as 
well as chelation of iron, accounting for almost half of TAC. Our meta-analysis identified a 
negative correlation between plasma uric acid levels and AD, similar to the dietary antioxidants 
considered. Uric acid levels were significantly lower in AD patients, even following sensitivity 
analysis, suggesting the findings of the meta-analysis were reliable.  
We found no significant difference in serum levels of two of the three xanthophylls considered 
but all members of both dietary antioxidant subclasses, carotenes and vitamins, were 
significantly reduced in AD. Our results suggest significantly reduced levels of dietary 
antioxidants that is not limited to the pro-vitamin A carotenoids (β-cryptoxanthin, α-carotene and 
β-carotene) but rather to their subclasses (xanthophylls, carotenes and vitamins), which may be 
of clinical significance.  Differential depletion among dietary antioxidants should be considered 
with respect to their properties such as water solubility, serum prevalence, and anti-oxidative 
capacity. The most prevalent exogenous antioxidants in plasma, which correlate with those most 
commonly found in the diet, are carotenes - lycopene and β-carotene. [65]. Under conditions of 
oxidative stress, carotenes, as a lipophilic carotenoid subclass, elute first and are preferentially 
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depleted. In contrast, the xanthophylls, which are more hydrophilic in nature, are more likely to 
deplete at a slower rate in plasma and tend to be retained longer [5, 66].  
The dominant carotenoids, lutein and zeaxanthin, exist at a 500 fold higher concentration in the 
brain and macula region of the eye than in the plasma, providing neuroprotection through multiple 
mechanisms, including control of free-radical mediated damage. In AD, the oxidative stressed 
brain may preferentially utilize xanthophylls from the large neural tissue reserves in the process of 
preserving homeostasis in the peripheral circulation until the latter stages of the disease. This 
theory is supported by findings from the EVA study, which found a reduction in plasma zeaxanthin 
levels among participants of the lowest cognitive functioning group as their ability to counteract 
the oxidative attack deteriorates [67]. Others studies have found no significant difference in plasma 
lutein levels between mild and moderate AD populations [18]. 
Sensitivity analyses identified significant heterogeneity among the xanthophyll class with Wang 
and colleagues reporting non-significant elevation of plasma lutein, zeaxanthin and β-
cryptoxanthin in mild and moderate AD patient groups but significantly lower levels in severe AD 
as defence mechanisms fail [22]. In the sensitivity analyses, the pooled effects showed 
significantly reduced levels of serum lutein, zeaxanthin and β-cryptoxanthin in individuals with 
AD following exclusion of this study.  
Collectively, our results suggest alterations in dietary antioxidant status are relevant within the 
sequelae of the disease. The lower plasma levels within the carotene and vitamin subclasses 
suggest patients with AD have impaired systemic availability of these exogenous antioxidants. 
Regardless of whether the antioxidant deficit was established from psychological factors resulting 
in micronutrient undernutrition or pathophysiological factors causing a pro-oxidative imbalance, 
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AD patients can be characterized as having disease-specific dietary requirements. The outcomes 
of our study highlight the importance of considering strategies to explore the potential utility of 
nutrition in AD prevention in order to compensate for the lower plasma antioxidant availability 
such as supplement use or increased intake of antioxidant-rich foods. 
Heterogeneity among studies included remains a considerable limitation of this meta-analysis 
approach. We attempted to minimize heterogeneity by limiting the meta-analyses to case-control 
study designs and, where supplements were used amongst subjects in certain studies, we extracted 
the data for non-supplement users to best represent habitual plasma levels.  
There were a number of further limitations of the data used within the meta-analyses. First, 
variations in the analysis methods used to quantify plasma antioxidant status in subjects may have 
had a significant influence on the heterogeneity detected. Second, the small sample size in the 
majority of studies remains a challenge through insufficient statistical power.  Several included 
studies failed to report data as parametric summary statistics. The transformations performed in 
our analysis were based on the assumption of normal distribution of data, which may not have 
been valid across all studies. Thirdly, variation in the characterization and classification of 
cognitively intact control samples may exist across studies and we made no attempt to censure 
this.  A further methodological limitation concerns the risk of biases associated with case-control 
study design. Our results are susceptible to reverse causation, as it is not possible to affirm whether 
the low levels of carotenoids and vitamins preceded or were the consequence of AD. Previously, 
hypotheses in support of lower levels of plasma antioxidant as a consequence of AD focused on 
a) diminished dietary intake of antioxidant-rich foods as a result of AD-related cognitive decline 
and b) the eventual exhaustion of antioxidant defenses due to increasing oxidative stress in severe 
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AD. Alternatively, older persons with AD may be at particular risk of poor nutrition for other 
reasons, including financial insecurity, medication use, poor dentition and decreased sense of taste 
and smell [68]. Furthermore, analyses were not performed separately for studies that used serum 
and plasma. Yu and colleagues reported a high correlation between plasma and serum 
measurements of metabolites overall (mean r 2= 0.81), although individual metabolite correlations 
between serum and plasma ranged from 0.01 to 0.96 [69]. Moreover, they reported higher 
sensitivity in biomarker detection from serum compared to plasma samples, although this had little 
bearing on their overall conclusions. 
Differential control of potential confounders across included studies is a further limitation to our 
study. Only a proportion of studies controlled for factors such as total energy intake, supplement 
use and smoking.  The inconsistent matching of patients with controls, even for age and sex, could 
in part confound our findings, given one third (17/52) of studies included did not achieve age and 
sex matching. We found that pooled effects of lutein, zeaxanthin and beta-cryptoxanthin reached 
significance (p<0.05) in a subgroup meta-analysis limited to studies with age and sex matching 
(data not shown). Furthermore, as one study was based on an all-female population [19], caution 
should be exercised given recent findings suggesting women have superior plasmatic antioxidant 
defenses [70]. It has been postulated that this sex discordance may be due to a combination of 
hormonal and lifestyle factors with a higher dietary intake of antioxidant-rich foods observed 
among women [71-73].  The failure of the majority of studies to provide data on antioxidant levels 
differentiated by gender, make such analyses extremely challenging. As increasing age and female 
gender are established risk factors of AD, we cannot exclude the possibility that dissimilar 
participant demographics may have confounded the apparent association between lower serum 
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antioxidant levels and AD. Finally, flavonoids were the only subclass of dietary antioxidant 
unaccounted in our study, as there was insufficient evidence from case-control studies to conduct 
a meta-analysis.  
Our data suggests that alterations in serum antioxidant levels may form part of the 
pathophysiological processes of AD and highlights the specific antioxidant requirements of these 
patients. This paper provides support for large, adequately powered, longitudinal case-control 
studies that should be conducted with better matching while examining differences between 
disease stages so that the transition point at which these changes occur in serum antioxidant levels 
can be determined. Such information could then inform the development of adequately powered 
RCTs. 
Moreover, the correction of the antioxidant imbalance via supplementation or dietary modification 
offers an important potential opportunity to modify AD risk or slow progression at various points 
in the disease spectrum. The introduction of feasible nutritional interventions with few side effects 
in AD prevention is of great importance in an emergent field of major public health concern. It is 
critical that future research acknowledges the limitations of past trials and consider the evidence-
based approach to study design for nutritional interventions, whether via diet or supplements, 
including consideration of dose, timing and specificity of antioxidant targeting. As such, future 
research focussing on trials designed to evaluate this hypothesis would advance our understanding 
of compromised antioxidant status in AD.  
In conclusion, our data confirms that patients with AD have a systemic antioxidant deficiency with 
significantly lower plasma levels found in eight of the ten antioxidants investigated. Although two 
antioxidants within the xanthophyll subclass failed to reach statistical significance, a strong trend 
20 
 
towards decreased levels in AD was observed. It is critical that future studies consider larger 
sample sizes and potential confounding to limit the impact of heterogeneity. Given these caveats, 
the evidence should be considered with caution to inform the design of future interventions in AD 
prevention.  
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Table 1.   Summary measures for the meta-analyzed data for the ten antioxidants investigated. 
Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; PMD, Pooled mean difference  
 
  
Antioxidant Studies Included 
Total N AD / 
control 
PMD (95% CI) 
moles/l 
Alpha-carotene 8 327 / 269 -0.03 [-0.05, -0.01]  
Beta-carotene 13 701 / 633 -0.11 [-0.17, -0.04]  
Lycopene 7 424 / 319 -0.15 [-0.27, -0.02]  
Beta-cryptoxanthin 4 174 / 145 -0.13 [-0.28,  0.01]  
Lutein 5 210 / 178 -0.13 [-0.23, -0.03]  
Zeaxanthin 5 210 / 178 -0.03 [-0.07,  0.00]  
Vitamin A  15 752 / 1104 -0.78 [-1.18, -0.39]  
Vitamin C 16 623 / 491 -12.6 [-17.7, -7.40]  
Vitamin E  31 1554 / 1872 -5.26 [-6.64, -3.89]  
Uric Acid 21 1110 / 2384 -27.4 [-49.8, -5.00]  
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Figure 1. PRISMA diagram of breakdown of publication selection  
Schematic detailing the search and sub-selection of case-control studies in the meta-
analysis. Studies were published from 1989 to September 2016.  
Abbreviations: WoS, Web of Science, AD, Alzheimer’s disease.   
Records excluded (n = 653) 
1. Conference papers, abstracts, reviews  
2. No antioxidant measurement 
3. Non-human subjects 
Total amount of records (n = 2508) 
Total records identified through database searching (n = 2489) 
PubMed 
1996-2016 
(n = 480) 
Embase 
1974-2016 
(n = 647) 
SCOPUS 
1996-2016 
(n = 777) 
ISI WoS 
1970-2016 
(n = 585)  
Additional records 
identified from other 
sources (n = 20) 
 
Removal of duplicates (n = 1753) 
Titles and abstracts screened (n = 755) 
Full text articles assessed for eligibility (n = 102) 
Total number of studies meeting inclusion criteria (n = 61) 
Records excluded (n = 41) 
1. Non-AD /combined dementia subtypes  
2. Control group not cognitively intact  
Total number of studies included in meta-analysis (n = 52) 
Records excluded (n = 9) 
1. Incomplete data sets 
2. Same patient population 
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